ARMOR (Analyzing Renal Mechanisms of creatinine excretion in patients On tesaglitazaR)

Study identifier:D6160C00040

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A 24-week, Randomised, Parallel-Group, Multi-Centre, Open-Label Study of the Renal Effects of Tesaglitazar in Patients with Type 2 Diabetes Mellitus

Medical condition

Diabetes Mellitus, Type 2

Phase

Phase 2

Healthy volunteers

No

Study drug

-

Sex

All

Actual enrollment

100

Study type

Interventional

Age

45 Years +

Date

Study Start Date: 01 Sept 2004
Primary Completion Date: 01 Jun 2006
Study Completion Date: 01 Jun 2006

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: None

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria